148 related articles for article (PubMed ID: 1376361)
1. Rapamycin and FK506 differentially inhibit mast cell cytokine production and cytokine-induced proliferation and act as reciprocal antagonists.
Hatfield SM; Mynderse JS; Roehm NW
J Pharmacol Exp Ther; 1992 Jun; 261(3):970-6. PubMed ID: 1376361
[TBL] [Abstract][Full Text] [Related]
2. Cyclosporine and FK506 inhibition of murine mast cell cytokine production.
Hatfield SM; Roehm NW
J Pharmacol Exp Ther; 1992 Feb; 260(2):680-8. PubMed ID: 1371158
[TBL] [Abstract][Full Text] [Related]
3. The immunosuppressive macrolides FK-506 and rapamycin act as reciprocal antagonists in murine T cells.
Dumont FJ; Melino MR; Staruch MJ; Koprak SL; Fischer PA; Sigal NH
J Immunol; 1990 Feb; 144(4):1418-24. PubMed ID: 1689353
[TBL] [Abstract][Full Text] [Related]
4. The hydroxylamine of sulfamethoxazole synergizes with FK506 and cyclosporin A, inhibiting T-cell proliferation.
Hess DA; Bird IA; Almawi WY; Rieder MJ
J Pharmacol Exp Ther; 1997 Apr; 281(1):540-8. PubMed ID: 9103542
[TBL] [Abstract][Full Text] [Related]
5. Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin.
Dumont FJ; Staruch MJ; Koprak SL; Melino MR; Sigal NH
J Immunol; 1990 Jan; 144(1):251-8. PubMed ID: 1688572
[TBL] [Abstract][Full Text] [Related]
6. The complex of FK506-binding protein 12 and FK506 inhibits calcineurin phosphatase activity and IgE activation-induced cytokine transcripts, but not exocytosis, in mouse mast cells.
Fruman DA; Bierer BE; Benes JE; Burakoff SJ; Austen KF; Katz HR
J Immunol; 1995 Feb; 154(4):1846-51. PubMed ID: 7530743
[TBL] [Abstract][Full Text] [Related]
7. Superior T-cell suppression by rapamycin and FK506 over rapamycin and cyclosporine A because of abrogated cytotoxic T-lymphocyte induction, impaired memory responses, and persistent apoptosis.
Koenen HJ; Michielsen EC; Verstappen J; Fasse E; Joosten I
Transplantation; 2003 May; 75(9):1581-90. PubMed ID: 12792519
[TBL] [Abstract][Full Text] [Related]
8. Effects of FK506 and cyclosporin A on cytokine production studied in vitro at a single-cell level.
Andersson J; Nagy S; Groth CG; Andersson U
Immunology; 1992 Jan; 75(1):136-42. PubMed ID: 1371491
[TBL] [Abstract][Full Text] [Related]
9. FK-506, a potent novel inhibitor of the release of proinflammatory mediators from human Fc epsilon RI+ cells.
de Paulis A; Cirillo R; Ciccarelli A; Condorelli M; Marone G
J Immunol; 1991 Apr; 146(7):2374-81. PubMed ID: 1706398
[TBL] [Abstract][Full Text] [Related]
10. Suppression of B cell activation by cyclosporin A, FK506 and rapamycin.
Wicker LS; Boltz RC; Matt V; Nichols EA; Peterson LB; Sigal NH
Eur J Immunol; 1990 Oct; 20(10):2277-83. PubMed ID: 1700753
[TBL] [Abstract][Full Text] [Related]
11. Transforming growth factor beta 1 inhibits interleukin-1-induced but enhances ionomycin-induced interferon-gamma production in a T cell lymphoma: comparison with the effects of rapamycin.
Dumont FJ; Kastner CA
J Cell Physiol; 1994 Jul; 160(1):141-53. PubMed ID: 8021294
[TBL] [Abstract][Full Text] [Related]
12. Rapamycin potentiates dexamethasone-induced apoptosis and inhibits JNK activity in lymphoblastoid cells.
Ishizuka T; Sakata N; Johnson GL; Gelfand EW; Terada N
Biochem Biophys Res Commun; 1997 Jan; 230(2):386-91. PubMed ID: 9016789
[TBL] [Abstract][Full Text] [Related]
13. Quantitative and temporal analysis of the cellular interaction of FK-506 and rapamycin in T-lymphocytes.
Dumont FJ; Kastner C; Iacovone F; Fischer PA
J Pharmacol Exp Ther; 1994 Jan; 268(1):32-41. PubMed ID: 7507994
[TBL] [Abstract][Full Text] [Related]
14. Dominant mutations confer resistance to the immunosuppressant, rapamycin, in variants of a T cell lymphoma.
Dumont FJ; Staruch MJ; Grammer T; Blenis J; Kastner CA; Rupprecht KM
Cell Immunol; 1995 Jun; 163(1):70-9. PubMed ID: 7538911
[TBL] [Abstract][Full Text] [Related]
15. A role for calcineurin in degranulation of murine cytotoxic T lymphocytes.
Dutz JP; Fruman DA; Burakoff SJ; Bierer BE
J Immunol; 1993 Apr; 150(7):2591-8. PubMed ID: 7681074
[TBL] [Abstract][Full Text] [Related]
16. Differential effects of rapamycin, cyclosporine A, and FK506 on human coronary artery smooth muscle cell proliferation and signalling.
Hafizi S; Mordi VN; Andersson KM; Chester AH; Yacoub MH
Vascul Pharmacol; 2004; 41(4-5):167-76. PubMed ID: 15607500
[TBL] [Abstract][Full Text] [Related]
17. Effect of cyclosporin and tacrolimus (FK506) on the antigen-induced mediator release, membrane potential and 86Rb+/K+ and Ca2+ fluxes in the RBL-2H3 cell line.
Narenjkar J; Assem el-SK; Wan BY; Marsh S; Ezeamuzie CI
Int Immunopharmacol; 2006 May; 6(5):742-9. PubMed ID: 16546704
[TBL] [Abstract][Full Text] [Related]
18. Effects of ciclosporin A, tacrolimus and sirolimus on cytokine production in neonatal immune cells.
Puzik A; Schultz C; Iblher P; Müller-Steinhardt M; Härtel C
Acta Paediatr; 2007 Oct; 96(10):1483-9. PubMed ID: 17880416
[TBL] [Abstract][Full Text] [Related]
19. Effects of rapamycin on growth factor-stimulated vascular smooth muscle cell DNA synthesis. Inhibition of basic fibroblast growth factor and platelet-derived growth factor action and antagonism of rapamycin by FK506.
Cao W; Mohacsi P; Shorthouse R; Pratt R; Morris RE
Transplantation; 1995 Feb; 59(3):390-5. PubMed ID: 7532879
[TBL] [Abstract][Full Text] [Related]
20. Novel immunosuppressive agent, FK506. In vitro effects on the cloned T cell activation.
Sawada S; Suzuki G; Kawase Y; Takaku F
J Immunol; 1987 Sep; 139(6):1797-803. PubMed ID: 2442255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
